Gina Columbus

Articles

Tafasitamab/Lenalidomide Combo Application Fast-Tracked in Europe

May 22nd 2020

The European Medicines Agency has validated a Marketing Authorization for the combination of tafasitamab and lenalidomide, followed by single-agent lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant.

FDA Grants Trastuzumab Deruxtecan Orphan Drug Status in Gastric Cancer

May 22nd 2020

The FDA has granted an orphan drug designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

ASCO 2020: Oncology Experts Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Innovative Combo Regimens Are Necessary in Heterogeneous Ovarian Cancer Population

May 3rd 2020

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

RAF-MEK Inhibitor/Defactinib Combo Is Active in KRAS-Mutant Cancers

April 30th 2020

The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.

Blood Test Is Feasible for Early Detection Across Multiple Cancers

April 29th 2020

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

TIL Therapy Elicits Encouraging Activity in Advanced NSCLC

April 29th 2020

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

Adding Durvalumab/Olaparib to Neoadjuvant Chemo Improves pCR in High-Risk HER2-Negative Breast Cancer

April 28th 2020

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

FDA Approves Ibrutinib/Rituximab for Frontline CLL/SLL

April 21st 2020

The FDA has approved an expanded indication of ibrutinib for use in combination with rituximab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

COVID-19 and Cancer Consortium Gains International Ground

April 18th 2020

Toni K. Choueiri, MD, shares updates regarding the COVID-19 and Cancer Consortium and other changes he has experienced in clinical practice due to the ongoing COVID-19 pandemic.

FDA Approves Pemigatinib for FGFR2+ Cholangiocarcinoma

April 18th 2020

The FDA has approved pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8th 2020

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

Niraparib/Bevacizumab Combo as Frontline Maintenance Shows Promise in Advanced Ovarian Cancer

April 8th 2020

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer

April 3rd 2020

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

March 31st 2020

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

March 30th 2020

The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care chemotherapy, which includes etoposide plus either carboplatin or cisplatin.

Rini Shares Challenges in Keeping Up With COVID-19 in Oncology

March 27th 2020

Brian I. Rini, MD, highlights the Uromigos podcast efforts to educate other oncologists on how COVID-19 will shift their practice, as well as adapting to changing procedures in clinic to continue delivering optimal care for patients with cancer during the pandemic.

From the Frontlines: Choueiri Talks Shift in GU Cancer Care in Wake of COVID-19

March 25th 2020

Toni K. Choueiri, MD, highlights the changes he has observed in clinical practice amidst the COVID-19 pandemic and the unified approach being taken at Dana-Farber Cancer Institute.

Cancer Registry Launches to Inform COVID19+ Patient Demographics

March 18th 2020

Jeremy L. Warner, MD, MS, discusses the goals of the COVID-19 and Cancer Consortium Registry, what other data need to be extrapolated with COVID-19, and how the virus could impact patients with cancer.